Targeted therapies in myeloid leukemia

Seminars in Cancer Biology

Volumn 14, Issue 1, 2004, Pages 41-62

  John, Alison M ^a   Thomas, N Shaun B ^a   Mufti, Ghulam J ^a   Padua, Rose Ann ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Differentiation therapy; Epigenetic silencing; Immunotherapy; Kinase inhibitors; Myeloid leukemia

Indexed keywords

4 [6 METHOXY 7 [3 (1 PIPERIDINYL)PROPOXY] 4 QUINAZOLINYL] 1 PIPERAZINECARBOXYLIC ACID (4 ISOPROPOXYPHENYL)AMIDE; 5 AZA 2' DEOXYCYTIDINE; 6,7 DIMETHOXY 2 PHENYLQUINOXALINE; 6,7 DIMETHYL 2 PHENYLQUINOXALINE; ANTINEOPLASTIC AGENT; BCR ABL PROTEIN; CEP 701; DNA VACCINE; FLT3 LIGAND; HERBIMYCIN A; HYBRID PROTEIN; IMATINIB; MIDOSTAURIN; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN P15; PROTEIN TYROSINE KINASE INHIBITOR; RAS PROTEIN; SEMAXANIB; STAT5 PROTEIN; STEM CELL FACTOR; SUNITINIB; TYROSINE KINASE RECEPTOR; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; CANCER CELL DESTRUCTION; CELL PROLIFERATION; CHROMOSOME TRANSLOCATION; DISEASE COURSE; ENZYME ACTIVATION; ENZYME INHIBITION; GENE SILENCING; HUMAN; MYELODYSPLASTIC SYNDROME; MYELOID LEUKEMIA; ONCOGENE; PANCYTOPENIA; PHILADELPHIA 1 CHROMOSOME; PROTEIN DEPHOSPHORYLATION; PROTEIN FAMILY; REVIEW; TARGET CELL DESTRUCTION;

EID: 0842286649     PISSN: 1044579X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semcancer.2003.11.006     Document Type: Review

References (337)

1. Knudson A.G. Jr. Mutation and cancer: statistical study of retinoblastoma. Proc. Natl. Acad. Sci. U.S.A. 68:1971;820-823.
2. Pitot H.C., Dragan Y.P. Facts and theories concerning the mechanisms of carcinogenesis. FASEB J. 5:1991;2280-2286.
3. Vogelstein B., Kinzler K.W. The multistep nature of cancer. Trends Genet. 9:1993;138-141.
4. Buggins A.G., Milojkovic D., Arno M.J., Lea N.C., Mufti G.J., Thomas N.S.et al. Microenvironment produced by acute myeloid leukemia cells prevents T cell activation and proliferation by inhibition of NF-kappaB, c-Myc, and pRb pathways. J. Immunol. 167:2001;6021-6030.
5. Green D.R., Evan G.I. A matter of life and death. Cancer Cell. 1:2002;19-30.
6. Morgenbesser S.D., Williams B.O., Jacks T., DePinho R.A. p53-dependent apoptosis produced by Rb-deficiency in the developing mouse lens. Nature. 371:1994;72-74.
7. Jackson-Grusby L. Modeling cancer in mice. Oncogene. 21:2002;5504-5514.
8. Pelengaris S., Khan M., Evan G. c-MYC: more than just a matter of life and death. Nat. Rev. Cancer. 2:2002;764-776.
9. Bartek J., Lukas J. Are all cancer genes equal? Nature. 411:2001;1001-1002.
10. Drayton S., Peters G. Immortalisation and transformation revisited. Curr. Opin. Genet. Dev. 12:2002;98-104.
11. Hahn W.C., Counter C.M., Lundberg A.S., Beijersbergen R.L., Brooks M.W., Weinberg R.A. Creation of human tumour cells with defined genetic elements. Nature. 400:1999;464-468.
12. Morales C.P., Holt S.E., Ouellette M., Kaur K.J., Yan Y., Wilson K.S.et al. Absence of cancer-associated changes in human fibroblasts immortalized with telomerase. Nat. Genet. 21:1999;115-118.
13. Elenbaas B., Spirio L., Koerner F., Fleming M.D., Zimonjic D.B., Donaher J.L.et al. Human breast cancer cells generated by oncogenic transformation of primary mammary epithelial cells. Genes Dev. 15:2001;50-65.
14. Lundberg A.S., Randell S.H., Stewart S.A., Elenbaas B., Hartwell K.A., Brooks M.W.et al. Immortalization and transformation of primary human airway epithelial cells by gene transfer. Oncogene. 21:2002;4577-4586.
15. Bennett J.M., Catovsky D., Daniel M.T., Flandrin G., Galton D.A., Gralnick H.R.et al. Proposals for the classification of the myelodysplastic syndromes. Br. J. Haematol. 51:1982;189-199.
16. Mufti G.J., Galton D.A. Myelodysplastic syndromes: natural history and features of prognostic importance. Clin. Haematol. 15:1986;953-971.
17. Fennaux P. Myelodysplastic syndromes. In: Degos L, Linch DC, Lowenberg B, editors. Textbook of malignant haematology, 1st ed. London: Martin Dunitz; 1999. p. 787-814.
18. Gallagher A., Darley R.L., Padua R. The molecular basis of myelodysplastic syndromes. Haematologica. 82:1997;191-204.
19. Padua R.A., McGlynn A., McGlynn H. Molecular, cytogenetic and genetic abnormalities in MDS and secondary AML. Cancer Treat. Res. 108:2001;111-157.
20. Pruneri G., Bertolini F., Soligo D., Carboni N., Cortelezzi A., Ferrucci P.F.et al. Angiogenesis in myelodysplastic syndromes. Br. J. Cancer. 81:1999;1398-1401.
21. de The H., Chomienne C., Lanotte M., Degos L., Dejean A. The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor alpha gene to a novel transcribed locus. Nature. 347:1990;558-561.
22. Borrow J., Goddard A.D., Sheer D., Solomon E. Molecular analysis of acute promyelocytic leukemia breakpoint cluster region on chromosome 17. Science. 249:1990;1577-1580.
23. Kakizuka A., Miller W.H. Jr., Umesono K., Warrell R.P. Jr., Frankel S.R., Murty V.V.et al. Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RAR alpha with a novel putative transcription factor, PML. Cell. 66:1991;663-674.
24. Alcalay M., Zangrilli D., Pandolfi P.P., Longo L., Mencarelli A., Giacomucci A.et al. Translocation breakpoint of acute promyelocytic leukemia lies within the retinoic acid receptor alpha locus. Proc. Natl. Acad. Sci. U.S.A. 88:1991;1977-1981.
25. Chen Z., Brand N.J., Chen A., Chen S.J., Tong J.H., Wang Z.Y.et al. Fusion between a novel Kruppel-like zinc finger gene and the retinoic acid receptor-alpha locus due to a variant t(11;17) translocation associated with acute promyelocytic leukaemia. EMBO J. 12:1993;1161-1167.
26. Redner R.L., Rush E.A., Faas S., Rudert W.A., Corey S.J. The t(5;17) variant of acute promyelocytic leukemia expresses a nucleophosmin-retinoic acid receptor fusion. Blood. 87:1996;882-886.
27. Wells R.A., Catzavelos C., Kamel-Reid S. Fusion of retinoic acid receptor alpha to NuMA, the nuclear mitotic apparatus protein, by a variant translocation in acute promyelocytic leukaemia. Nat. Genet. 17:1997;109-113.
28. Arnould C., Philippe C., Bourdon V., Grgoire M.J., Berger R., Jonveaux P. The signal transducer and activator of transcription STAT5b gene is a new partner of retinoic acid receptor alpha in acute promyelocytic-like leukaemia. Hum. Mol. Genet. 8:1999;1741-1749.
29. Fenaux P., Castaigne S., Dombret H., Archimbaud E., Duarte M., Morel P. et al. All-trans-retinoic acid followed by intensive chemotherapy gives a high complete remission rate and may prolong remissions in newly diagnosed acute promyelocytic leukemia: a pilot study on 26 cases. Blood. 80:1992;2176-2181.
30. Fenaux P., Chomienne C., Degos L. Treatment of acute promyelocytic leukaemia. Best Pract. Res. Clin. Haematol. 14:2001;153-174.
31. Dombret H., Fenaux P., Soignet S.L., Tallman M.S. Established practice in the treatment of patients with acute promyleocytic leukemia and the introduction of arsenic trioxide as a novel therapy. Semin. Hematol. 39:2002;8-13.
32. Tallman M.S., Andersen J.W., Schiffer C.A., Appelbaum F.R., Feusner J.H., Woods W.G.et al. All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol. Blood. 100:2002;4298-4302.
33. Parmar S., Tallman M.S. Acute promyelocytic leukaemia: a review. Expert Opin. Pharmacother. 4:2003;1379-1392.
34. So C.W., Dong S., So C.K., Cheng G.X., Huang Q.H., Chen S.J.et al. The impact of differential binding of wild-type RARalpha, PML-, PLZF- and NPM-RARalpha fusion proteins towards transcriptional co-activator, RIP-140, on retinoic acid responses in acute promyelocytic leukemia. Leukemia. 14:2000;77-83.
35. Hong S.H., David G., Wong C.W., Dejean A., Privalsky M.L. SMRT corepressor interacts with PLZF and with the PML-retinoic acid receptor alpha (RARalpha) and PLZF-RARalpha oncoproteins associated with acute promyelocytic leukemia. Proc. Natl. Acad. Sci. U.S.A. 94:1997;9028-9033.
36. Lin R.J., Nagy L., Inoue S., Shao W., Miller W.H. Jr., Evans R.M. Role of the histone deacetylase complex in acute promyelocytic leukaemia. Nature. 391:1998;811-814.
37. Lin R.J., Sternsdorf T., Tini M., Evans R.M. Transcriptional regulation in acute promyelocytic leukemia. Oncogene. 20:2001;7204-7215.
38. Grignani F., De Matteis S., Nervi C., Tomassoni L., Gelmetti V., Cioce M.et al. Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia. Nature. 391:1998;815-818.
39. Guidez F., Ivins S., Zhu J., Soderstrom M., Waxman S., Zelent A. Reduced retinoic acid-sensitivities of nuclear receptor corepressor binding to PML- and PLZF-RARalpha underlie molecular pathogenesis and treatment of acute promyelocytic leukemia. Blood. 91:1998;2634-2642.
40. Kogan S.C. Acute promyelocytic leukemia: a view from a mouse. Blood Cells Mol. Dis. 26:2000;620-625.
41. Pandolfi P.P. In vivo analysis of the molecular genetics of acute promyelocytic leukemia. Oncogene. 20:2001;5726-5735.
42. Lallemand-Breitenbach V., Guillemin M.C., Janin A., Daniel M.T., Degos L., Kogan S.C.et al. Retinoic acid and arsenic synergize to eradicate leukemic cells in a mouse model of acute promyelocytic leukemia. J. Exp. Med. 189:1999;1043-1052.
43. 3 treatment in transgenic models of acute promyelocytic leukemia (APL) unravel the distinct nature of the leukemogenic process induced by the PML-RARalpha and PLZF-RARalpha oncoproteins. Proc. Natl. Acad. Sci. U.S.A. 97:2000;10173-10178.
44. Liu P., Han Z.C. Treatment of acute promyelocytic leukemia and other hematologic malignancies with arsenic trioxide: review of clinical and basic studies. Int. J. Hematol. 78:2003;32-39.
45. Ohno R., Asou N., Ohnishi K. Treatment of acute promyelocytic leukemia: strategy toward further increase of cure rate. Leukemia. 17:2003;1454-1463.
46. Raffoux E., Rousselot P., Poupon J., Daniel M.T., Cassinat B., Delarue R.et al. Combined treatment with arsenic trioxide and all-trans-retinoic acid in patients with relapsed acute promyelocytic leukemia. J. Clin. Oncol. 21:2003;2326-2334.
47. Zhu J., Koken M.H., Quignon F., Chelbi-Alix M.K., Degos L., Wang Z.Y.et al. Arsenic-induced PML targeting onto nuclear bodies: implications for the treatment of acute promyelocytic leukemia. Proc. Natl. Acad. Sci. U.S.A. 94:1997;3978-3983.
48. Davison K., Mann K.K., Miller W.H. Jr. Arsenic trioxide: mechanisms of action. Semin. Hematol. 39:2002;3-7.
49. Yergeau D.A., Hetherington C.J., Wang Q., Zhang P., Sharpe A.H., Binder M.et al. Embryonic lethality and impairment of haematopoiesis in mice heterozygous for an AML1-ETO fusion gene. Nat. Genet. 15:1997;303-306.
50. Castilla L.H., Wijmenga C., Wang Q., Stacy T., Speck N.A., Eckhaus M.et al. Failure of embryonic hematopoiesis and lethal hemorrhages in mouse embryos heterozygous for a knocked-in leukemia gene CBFB-MYH11. Cell. 87:1996;687-696.
51. Friedman A.D. Leukemogenesis by CBF oncoproteins. Leukemia. 13:1999;1932-1942.
52. Melnick A., Licht J.D. Histone deacetylases as therapeutic targets in hematologic malignancies. Curr. Opin. Hematol. 9:2002;322-332.
53. Redner R.L., Wang J., Liu J.M. Chromatin remodeling and leukemia: new therapeutic paradigms. Blood. 94:1999;417-428.
54. Durst K.L., Lutterbach B., Kummalue T., Friedman A.D., Hiebert S.W. The inv(16) fusion protein associates with corepressors via a smooth muscle myosin heavy-chain domain. Mol. Cell Biol. 23:2003;607-619.
55. Nucifora G., Rowley J.D. The AML1 gene in the 8;21 and 3;21 translocations in chronic and acute myeloid leukemia. Cold Spring Harb. Symp. Quant. Biol. 59:1994;595-605.
56. Roulston D., Espinosa R. III, Nucifora G., Larson R.A., Le Beau M.M., Rowley J.D. CBFA2(AML1) translocations with novel partner chromosomes in myeloid leukemias: association with prior therapy. Blood. 92:1998;2879-2885.
57. Cuenco G.M., Nucifora G., Ren R. Human AML1/MDS1/EVI1 fusion protein induces an acute myelogenous leukemia (AML) in mice: a model for human AML. Proc. Natl. Acad. Sci. U.S.A. 97:2000;1760-1765.
58. Wang J., Saunthararajah Y., Redner R.L., Liu J.M. Inhibitors of histone deacetylase relieve ETO-mediated repression and induce differentiation of AML1-ETO leukemia cells. Cancer Res. 59:1999;2766-2769.
59. Rowley J.D. Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature. 243:1973;290-293.
60. Nowell P.C., Hungerford D.A. A minute chromosome in human chronic granulocytic leukemia. Science. 132:1960;1497.
61. Guilhot F. Chronic myeloid leukaemia. In: Degos L, Linch DC, Lowenberg B, editors. Textbook of malignant haematology. London: Martin Dunitz; 1999. p. 815-45.
62. Lanza F.B.S. Role of p53 in leukemogenesis of chronic myeloid leukemia. Stem Cells. 13:1995;445-452.
63. Furukawa Y., DeCaprio J.A., Belvin M., Griffin J.D. Heterogeneous expression of the product of the retinoblastoma susceptibility gene in primary human leukemia cells. Oncogene. 6:1991;1343-1346.
64. Towatari M., Adachi K., Kato H., Saito H. Absence of the human retinoblastoma gene product in the megakaryoblastic crisis of chronic myelogenous leukemia. Blood. 78:1991;2178-2181.
65. Ishikura H., Yufu Y., Yamashita S., Abe Y., Okamura T., Motomura S.et al. Biphenotypic blast crisis of chronic myelogenous leukemia: abnormalities of p53 and retinoblastoma genes. Leuk. Lymphoma. 25:1997;573-578.
66. Serra A., Gottardi E., Della Ragione F., Saglio G., Iolascon A. Involvement of the cyclin-dependent kinase-4 inhibitor (CDKN2) gene in the pathogenesis of lymphoid blast crisis of chronic myelogenous leukaemia. Br. J. Haematol. 91:1995;625-629.
67. Nguyen T.T., Mohrbacher A.F., Tsai Y.C., Groffen J., Heisterkamp N., Nichols P.W.et al. Quantitative measure of c-abl and p15 methylation in chronic myelogenous leukemia: biological implications. Blood. 95:2000;2990-2992.
68. Daley G.Q., Van Etten R.A., Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science. 247:1990;824-830.
69. Goga A., McLaughlin J., Afar D.E., Saffran D.C., Witte O.N. Alternative signals to RAS for hematopoietic transformation by the BCR-ABL oncogene. Cell. 82:1995;981-988.
70. Sakai N., Ogiso Y., Fujita H., Watari H., Koike T., Kuzumaki N. Induction of apoptosis by a dominant negative H-RAS mutant (116Y) in K562 cells. Exp. Cell Res. 215:1994;131-136.
71. Sawyers C.L., Callahan W., Witte O.N. Dominant negative MYC blocks transformation by ABL oncogenes. Cell. 70:1992;901-910.
72. 1-to-S phase transition in hematopoietic cells. Oncogene. 15:1997;2333-2342.
73. Carlesso N., Frank D.A., Griffin J.D. Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines transformed by Bcr/Abl. J. Exp. Med. 183:1996;811-820.
74. Shuai K., Halpern J., ten Hoeve J., Rao X., Sawyers C.L. Constitutive activation of STAT5 by the BCR-ABL oncogene in chronic myelogenous leukemia. Oncogene. 13:1996;247-254.
75. Sattler M., Salgia R., Okuda K., Uemura N., Durstin M.A., Pisick E.et al. The proto-oncogene product p120CBL and the adaptor proteins CRKL and c-CRK link c-ABL, p190BCR/ABL and p210BCR/ABL to the phosphatidylinositol-3′ kinase pathway. Oncogene. 12:1996;839-846.
76. Sattler M., Verma S., Byrne C.H., Shrikhande G., Winkler T., Algate P.A.et al. BCR/ABL directly inhibits expression of SHIP, an SH2-containing polyinositol-5-phosphatase involved in the regulation of hematopoiesis. Mol. Cell Biol. 19:1999;7473-7480.
77. Guo X.Y., Balague C., Wang T., Randhawa G., Yuan Z., Bachier C.et al. The presence of the Rb c-box peptide in the cytoplasm inhibits p210bcr-abl transforming function. Oncogene. 18:1999;1589-1595.
78. Whitaker L.L., Su H., Baskaran R., Knudsen E.S., Wang J.Y. Growth suppression by an E2F-binding-defective retinoblastoma protein (RB): contribution from the RB C pocket. Mol. Cell Biol. 18:1998;4032-4042.
79. Amarante-Mendes G.P., Naekyung Kim C., Liu L., Huang Y., Perkins C.L., Green D.R.et al. Bcr-Abl exerts its antiapoptotic effect against diverse apoptotic stimuli through blockage of mitochondrial release of cytochrome C and activation of caspase-3. Blood. 91:1998;1700-1705.
80. Bedi A., Barber J.P., Bedi G.C., el-Deiry W.S., Sidransky D., Vala M.S. et al. BCR-ABL-mediated inhibition of apoptosis with delay of G2/M transition after DNA damage: a mechanism of resistance to multiple anticancer agents. Blood. 86:1995;1148-1158.
81. Sanchez-Garcia I., Grutz G. Tumorigenic activity of the BCR-ABL oncogenes is mediated by BCL2. Proc. Natl. Acad. Sci. U.S.A. 92:1995;5287-5291.
82. Dunbar C.E., Crosier P.S., Nienhuis A.W. Introduction of an activated RAS oncogene into murine bone marrow lymphoid progenitors via retroviral gene transfer results in thymic lymphomas. Oncogene Res. 6:1991;39-51.
83. McGlave P.B., De Fabritiis P., Deisseroth A., Goldman J., Barnett M., Reiffers J.et al. Autologous transplants for chronic myelogenous leukaemia: results from eight transplant groups. Lancet. 343:1994;1486-1488.
84. Carella A.M., Chimirri F., Podesta M., Pitto A., Piaggio G., Dejana A.et al. High-dose chemo-radiotherapy followed by autologous Philadelphia chromosome-negative blood progenitor cell transplantation in patients with chronic myelogenous leukemia. Bone Marrow Transplant. 17:1996;201-205.
85. Carella A.M., Cunningham I., Lerma E., Dejana A., Benvenuto F., Podesta M.et al. Mobilization and transplantation of Philadelphia-negative peripheral-blood progenitor cells early in chronic myelogenous leukemia. J. Clin. Oncol. 15:1997;1575-1582.
86. de Fabritiis P., Petti M.C., Montefusco E., De Propris M.S., Sala R., Bellucci R.et al. BCR-ABL antisense oligodeoxynucleotide in vitro purging and autologous bone marrow transplantation for patients with chronic myelogenous leukemia in advanced phase. Blood. 91:1998;3156-3162.
87. Deininger M.W., Goldman J.M., Lydon N., Melo J.V. The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells. Blood. 90:1997;3691-3698.
88. Buchdunger E., Zimmermann J., Mett H., Meyer T., Muller M., Druker B.J. et al. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res. 56:1996;100-104.
89. Okuda K., Weisberg E., Gilliland D.G., Griffin J.D. ARG tyrosine kinase activity is inhibited by STI571. Blood. 97:2001;2440-2448.
90. Capdeville R., Buchdunger E., Zimmermann J., Matter A. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat. Rev. Drug Discov. 1:2002;493-502.
91. Druker B.J., Tamura S., Buchdunger E., Ohno S., Segal G.M., Fanning S.et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat. Med. 2:1996;561-566.
92. + progenitor cells from CML patients using the tyrosine kinase inhibitor CGP57148B. Anticancer Res. 20:2000;809-814.
93. Oetzel C., Jonuleit T., Gotz A., van der Kuip H., Michels H., Duyster J.et al. The tyrosine kinase inhibitor CGP 57148 (ST1 571) induces apoptosis in BCR-ABL-positive cells by down-regulating BCL-X. Clin. Cancer Res. 6:2000;1958-1968.
94. Beran M., Cao X., Estrov Z., Jeha S., Jin G., O'Brien S.et al. Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148). Clin. Cancer Res. 4:1998;1661-1672.
95. Gambacorti-Passerini C., le Coutre P., Mologni L., Fanelli M., Bertazzoli C., Marchesi E.et al. Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis. Blood Cells Mol. Dis. 23:1997;380-394.
96. Gesbert F, Sellers WR, Signoretti S, Loda M, Griffin JD. BCR/ABL regulates expression of the cyclin dependent kinase inhibitor p27Kip1 through the PI3K/AKT pathway. J Biol Chem 2000.
97. Parada Y., Banerji L., Glassford J., Lea N.C., Collado M., Rivas C.et al. BCR-ABL and interleukin 3 promote haematopoietic cell proliferation and survival through modulation of cyclin D2 and p27Kip1 expression. J. Biol. Chem. 276:2001;23572-23580.
98. Komatsu N., Watanabe T., Uchida M., Mori M., Kirito K., Kikuchi S.et al. A member of Forkhead transcription factor FKHRL1 is a downstream effector of STI571-induced cell cycle arrest in BCR-ABL-expressing cells. J. Biol. Chem. 278:2003;6411-6419.
99. Shuster C.B., Herman I.M. The mechanics of vascular cell motility. Microcirculation. 5:1998;239-257.
100. Dan S., Naito M., Tsuruo T. Selective induction of apoptosis in Philadelphia chromosome-positive chronic myelogenous leukemia cells by an inhibitor of BCR-ABL tyrosine kinase, CGP 57148. Cell Death Differ. 5:1998;710-715.
101. Druker B.J., Talpaz M., Resta D.J., Peng B., Buchdunger E., Ford J.M.et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 344:2001;1031-1037.
102. O'Brien S.G., Guilhot F., Larson R.A., Gathmann I., Baccarani M., Cervantes F.et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N. Engl. J. Med. 348:2003;994-1004.
103. Gorre M.E., Mohammed M., Ellwood K., Hsu N., Paquette R., Rao P.N.et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science. 293:2001;876-880.
104. Roumiantsev S., Shah N.P., Gorre M.E., Nicoll J., Brasher B.B., Sawyers C.L.et al. Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop. Proc. Natl. Acad. Sci. U.S.A. 99:2002;10700-10705.
105. Heinrich M.C., Griffith D.J., Druker B.J., Wait C.L., Ott K.A., Zigler A.J. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood. 96:2000;925-932.
106. van Oosterom A.T., Judson I.R., Verweij J., Stroobants S., Dumez H., Donato di Paola E.et al. Update of phase I study of imatinib (STI571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors: a report of the EORTC Soft Tissue and Bone Sarcoma Group. Eur. J. Cancer. 38(Suppl. 5):2002;S83-S87.
107. Dagher R., Cohen M., Williams G., Rothmann M., Gobburu J., Robbie G.et al. Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors. Clin. Cancer Res. 8:2002;3034-3038.
108. Heinrich M.C., Blanke C.D., Druker B.J., Corless C.L. Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies. J. Clin. Oncol. 20:2002;1692-1703.
109. Sattler M., Scheijen B., Weisberg E., Griffin J.D. Mutated tyrosine kinases as therapeutic targets in myeloid leukemias. Adv. Exp. Med. Biol. 532:2003;121-140.
110. Cortes J., Giles F., O'Brien S., Thomas D., Albitar M., Rios M.B.et al. Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders. Cancer. 97:2003;2760-2766.
111. George D. Targeting PDGF receptors in cancer-rationales and proof of concept clinical trials. Adv. Exp. Med. Biol. 532:2003;141-151.
112. Apperley J.F., Gardembas M., Melo J.V., Russell-Jones R., Bain B.J., Baxter E.J.et al. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N. Engl. J. Med. 347:2002;481-487.
113. Thiede C., Steudel C., Mohr B., Schaich M., Schakel U., Platzbecker U.et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood. 99:2002;4326-4335.
114. Yamamoto Y., Kiyoi H., Nakano Y., Suzuki R., Kodera Y., Miyawaki S.et al. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood. 97:2001;2434-2439.
115. Schnittger S., Schoch C., Dugas M., Kern W., Staib P., Wuchter C.et al. Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood. 100:2002;59-66.
116. Gutkind J.S. Cell growth control by G protein-coupled receptors: from signal transduction to signal integration. Oncogene. 17:1998;1331-1342.
117. Hoefsloot L.H., van Amelsvoort M.P., Broeders L.C., van der Plas D.C., van Lom K., Hoogerbrugge H.et al. Erythropoietin-induced activation of STAT5 is impaired in the myelodysplastic syndrome. Blood. 89:1997;1690-1700.
118. Levis M., Tse K.F., Smith B.D., Garrett E., Small D. A FLT3 tyrosine kinase inhibitor is selectively cytotoxic to acute myeloid leukemia blasts harboring FLT3 internal tandem duplication mutations. Blood. 98:2001;885-887.
119. Tse K.F., Novelli E., Civin C.I., Bohmer F.D., Small D. Inhibition of FLT3-mediated transformation by use of a tyrosine kinase inhibitor. Leukemia. 15:2001;1001-1010.
120. Zhao M., Kiyoi H., Yamamoto Y., Ito M., Towatari M., Omura S.et al. In vivo treatment of mutant FLT3-transformed murine leukemia with a tyrosine kinase inhibitor. Leukemia. 14:2000;374-378.
121. Kelly L.M., Liu Q., Kutok J.L., Williams I.R., Boulton C.L., Gilliland D.G. FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model. Blood. 99:2002;310-318.
122. Yee K.W., O'Farrell A.M., Smolich B.D., Cherrington J.M., McMahon G., Wait C.L.et al. SU5416 and SU5614 inhibit kinase activity of wild-type and mutant FLT3 receptor tyrosine kinase. Blood. 100:2002;2941-2949.
123. George D.J., Dionne C.A., Jani J., Angeles T., Murakata C., Lamb J.et al. Sustained in vivo regression of Dunning H rat prostate cancers treated with combinations of androgen ablation and Trk tyrosine kinase inhibitors, CEP-751 (KT-6587) or CEP-701 (KT-5555). Cancer Res. 59:1999;2395-2401.
124. Weisberg E., Boulton C., Kelly L.M., Manley P., Fabbro D., Meyer T.et al. Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412. Cancer Cell. 1:2002;433-443.
125. O'Farrell A.M., Abrams T.J., Yuen H.A., Ngai T.J., Louie S.G., Yee K.W. et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood. 101:2003;3597-3605.
126. Martinelli G., Piccaluga P.P., Lo Coco F. FLT3 inhibition as tailored therapy for acute myeloid leukemia. Haematologica. 88:2003;4-8.
127. Fong T.A., Shawver L.K., Sun L., Tang C., App H., Powell T.J.et al. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res. 59:1999;99-106.
128. Smolich B.D., Yuen H.A., West K.A., Giles F.J., Albitar M., Cherrington J.M. The antiangiogenic protein kinase inhibitors SU5416 and SU6668 inhibit the SCF receptor (c-kit) in a human myeloid leukemia cell line and in acute myeloid leukemia blasts. Blood. 97:2001;1413-1421.
129. Fiedler W, Mesters R, Tinnefeld H, Loges S, Staib P, Duhrsen U, et al. A phase II clinical study of SU5416 in patients with refractory acute myeloid leukemia. Blood 2003.
130. Sawyers C.L. Finding the next Gleevec: FLT3 targeted kinase inhibitor therapy for acute myeloid leukemia. Cancer Cell. 1:2002;413-415.
131. Mendel D.B., Laird A.D., Xin X., Louie S.G., Christensen J.G., Li G.et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin. Cancer Res. 9:2003;327-337.
132. Gallagher A.P., Burnett A.K., Bowen D.T., Darley R.L. Mutant RAS selectively promotes sensitivity of myeloid leukemia cells to apoptosis by a protein kinase C-dependent process. Cancer Res. 58:1998;2029-2035.
133. Padua R.A., Guinn B.A., Al-Sabah A.I., Smith M., Taylor C., Pettersson T.et al. RAS, FMS and p53 mutations and poor clinical outcome in myelodysplasias: a 10-year follow-up. Leukemia. 12:1998;887-892.
134. Yunis J.J., Boot A.J., Mayer M.G., Bos J.L. Mechanisms of ras mutation in myelodysplastic syndrome. Oncogene. 4:1989;609-614.
135. Gallagher A., Darley R., Padua R.A. RAS and the myelodysplastic syndromes. Pathol. Biol. Paris. 45:1997;561-568.
136. Ahmadian M.R., Zor T., Vogt D., Kabsch W., Selinger Z., Wittinghofer A. et al. Guanosine triphosphatase stimulation of oncogenic Ras mutants. Proc. Natl. Acad. Sci. U.S.A. 96:1999;7065-7070.
137. Darley R.L., Hoy T.G., Baines P., Padua R.A., Burnett A.K. Mutant N-RAS induces erythroid lineage dysplasia in human CD34+ cells. J. Exp. Med. 185:1997;1337-1347.
138. McGlynn A.P., Padua R.A., Burnett A.K., Darley R.L. Alternative effects of RAS and RAF oncogenes on the proliferation and apoptosis of factor-dependent FDC-P1 cells. Leuk. Res. 24:2000;47-54.
139. Borner C., Schlagbauer Wadl H., Fellay I., Selzer E., Polterauer P., Jansen B. Mutated N-ras upregulates Bcl-2 in human melanoma in vitro and in SCID mice. Melanoma Res. 9:1999;347-350.
140. Tombor B., Rundell K., Oltvai Z.N. Bcl-2 promotes premature senescence induced by oncogenic Ras. Biochem. Biophys. Res. Commun. 303:2003;800-807.
141. Petrenko O., Zaika A., Moll U.M. deltaNp73 facilitates cell immortalization and cooperates with oncogenic Ras in cellular transformation in vivo. Mol. Cell Biol. 23:2003;5540-5555.
142. Chin L., Tam A., Pomerantz J., Wong M., Holash J., Bardeesy N.et al. Essential role for oncogenic Ras in tumour maintenance. Nature. 400:1999;468-472.
143. Adams J.M., Cory S. Oncogene co-operation in leukaemogenesis. Cancer Surv. 15:1992;119-141.
144. Haupt Y., Harris A.W., Adams J.M. Retroviral infection accelerates T lymphomagenesis in E mu-N-ras transgenic mice by activating c-myc or N-myc. Oncogene. 7:1992;981-986.
145. Hawley R.G., Fong A.Z., Ngan B.Y., Hawley T.S. Hematopoietic transforming potential of activated ras in chimeric mice. Oncogene. 11:1995;1113-1123.
146. Maher J., Baker D.A., Manning M., Dibb N.J., Roberts I.A. Evidence for cell-specific differences in transformation by N-, H- and K-ras. Oncogene. 11:1995;1639-1647.
147. Kogan S.C., Lagasse E., Atwater S., Bae S.C., Weissman I., Ito Y.et al. The PEBP2betaMYH11 fusion created by Inv(16)(p13;q22) in myeloid leukemia impairs neutrophil maturation and contributes to granulocytic dysplasia. Proc. Natl. Acad. Sci. U.S.A. 95:1998;11863-11868.
148. MacKenzie K.L., Dolnikov A., Millington M., Shounan Y., Symonds G. Mutant N-ras induces myeloproliferative disorders and apoptosis in bone marrow repopulated mice. Blood. 93:1999;2043-2056.
149. Lowy D.R., Willumsen B.M. Function and regulation of ras. Annu. Rev. Biochem. 62:1993;851-891.
150. Zhang B., Prendergast G.C., Fenton R.G. Farnesyltransferase inhibitors reverse Ras-mediated inhibition of Fas gene expression. Cancer Res. 62:2002;450-458.
151. Morgan M.A., Wegner J., Aydilek E., Ganser A., Reuter C.W. Synergistic cytotoxic effects in myeloid leukemia cells upon cotreatment with farnesyltransferase and geranylgeranyl transferase-I inhibitors. Leukemia. 17:2003;1508-1520.
152. Lobell R.B., Omer C.A., Abrams M.T., Bhimnathwala H.G., Brucker M.J., Buser C.A.et al. Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models. Cancer Res. 61:2001;8758-8768.
153. Rose W.C., Lee F.Y., Fairchild C.R., Lynch M., Monticello T., Kramer R.A.et al. Preclinical antitumor activity of BMS-214662, a highly apoptotic and novel farnesyltransferase inhibitor. Cancer Res. 61:2001;7507-7517.
154. Omer C.A., Chen Z., Diehl R.E., Conner M.W., Chen H.Y., Trumbauer M.E.et al. Mouse mammary tumor virus-Ki-rasB transgenic mice develop mammary carcinomas that can be growth-inhibited by a farnesyl:protein transferase inhibitor. Cancer Res. 60:2000;2680-2688.
155. Lancet J.E., Rosenblatt J.D., Karp J.E. Farnesyltransferase inhibitors and myeloid malignancies: phase I evidence of Zarnestra activity in high-risk leukemias. Semin. Hematol. 39:2002;31-35.
156. Karp J.E. Farnesyl protein transferase inhibitors as targeted therapies for hematologic malignancies. Semin. Hematol. 38:2001;16-23.
157. Kurzrock R., Cortes J., Kantarjian H. Clinical development of farnesyltransferase inhibitors in leukemias and myelodysplastic syndrome. Semin. Hematol. 39:2002;20-24.
158. Peters D.G., Hoover R.R., Gerlach M.J., Koh E.Y., Zhang H., Choe K.et al. Activity of the farnesyl protein transferase inhibitor SCH66336 against BCR/ABL-induced murine leukemia and primary cells from patients with chronic myeloid leukemia. Blood. 97:2001;1404-1412.
159. Ribrag V., Suzan F., Ravoet C., Feremans W., Guerci A., Dreyfus F.et al. Phase II trial of CPT-11 in myelodysplastic syndromes with excess of marrow blasts. Leukemia. 17:2003;319-322.
160. Topaly J., Fruehauf S., Ho A.D., Zeller W.J. Rationale for combination therapy of chronic myelogenous leukaemia with imatinib and irradiation or alkylating agents: implications for pretransplant conditioning. Br. J. Cancer. 86:2002;1487-1493.
161. Pines J. Cyclins and cyclin-dependent kinases: a biochemical view. Biochem. J. 308(Pt 3):1995;697-711.
162. Tassan J.P., Jaquenoud M., Leopold P., Schultz S.J., Nigg E.A. Identification of human cyclin-dependent kinase 8, a putative protein kinase partner for cyclin C. Proc. Natl. Acad. Sci. U.S.A. 92:1995;8871-8875.
163. Napolitano G., Majello B., Lania L. Role of cyclinT/Cdk9 complex in basal and regulated transcription (review). Int. J. Oncol. 21:2002;171-177.
164. Kasten M., Giordano A. Cdk10, a Cdc2-related kinase, associates with the Ets2 transcription factor and modulates its transactivation activity. Oncogene. 20:2001;1832-1838.
165. Hall M., Bates S., Peters G. Evidence for different modes of action of cyclin-dependent kinase inhibitors: p15 and p16 bind to kinases, p21 and p27 bind to cyclins. Oncogene. 11:1995;1581-1588.
166. Thomas NSB. Cell cycle regulation. In: Degos L, Griffin JD, Linch DC, Lowenberg B, editors. Textbook of malignant haematology, 2nd ed. London: Martin Dunitz; 2003, in press.
167. 0 cells. Science. 296:2002;1132-1136.
168. Friend S.H., Bernards R., Rogelj S., Weinberg R.A., Rapaport J.M., Albert D.M.et al. A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma. Nature. 323:1986;643-646.
169. Godbout R., Dryja T.P., Squire J., Gallie B.L., Phillips R.A. Somatic inactivation of genes on chromosome 13 is a common event in retinoblastoma. Nature. 304:1983;451-453.
170. Jamal R., Gale R.E., Shaun N., Thomas B., Wheatley K., Linch D.C. The retinoblastoma gene (rb1) in acute myeloid leukaemia: analysis of gene rearrangements, protein expression and comparison of disease outcome. Br. J. Haematol. 94:1996;342-351.
171. Zhu Y.M., Haynes A.P., Keith F.J., Russell N.H. Abnormalities of retinoblastoma gene expression in hematological malignancies. Leuk. Lymphoma. 18:1995;61-67.
172. Jamal R. The retinoblastoma gene in myeloid leukaemias. Hematology. 1:1996;43-51.
173. Tsai T., Davalath S., Rankin C., Radich J.P., Head D., Appelbaum F.R.et al. Tumor suppressor gene alteration in adult acute lymphoblastic leukemia (ALL). Analysis of retinoblastoma (Rb) and p53 gene expression in lymphoblasts of patients with de novo, relapsed, or refractory all treated in Southwest Oncology Group studies. Leukemia. 10:1996;1901-1910.
174. Sanchez-Beato M., Camacho F.I., Martinez-Montero J.C., Saez A.I., Villuendas R., Sanchez-Verde L.et al. Anomalous high p27/KIP1 expression in a subset of aggressive B-cell lymphomas is associated with cyclin D3 overexpression. p27/KIP1-cyclin D3 colocalization in tumor cells. Blood. 94:1999;765-772.
175. Morente M.M., Piris M.A., Abraira V., Acevedo A., Aguilera B., Bellas C.et al. Adverse clinical outcome in Hodgkin's disease is associated with loss of retinoblastoma protein expression, high Ki67 proliferation index, and absence of Epstein-Barr virus-latent membrane protein 1 expression. Blood. 90:1997;2429-2436.
176. Sauerbrey A., Stammler G., Zintl F., Volm M. Expression of the retinoblastoma tumor suppressor gene (RB-1) in acute leukemia. Leuk. Lymphoma. 28:1998;275-283.
177. Zhu Y.M., Bradbury D., Russell N. Decreased retinoblastoma protein expression in acute myeloblastic leukaemia is associated with the autonomous proliferation of clonogenic blasts. Br. J. Haematol. 86:1994;533-539.
178. Zhu Y.M., Bradbury D.A., Keith F.J., Russell N. Absence of retinoblastoma protein expression results in autocrine production of interleukin-6 and promotes the autonomous growth of acute myeloid leukemia blast cells. Leukemia. 8:1994;1982-1988.
179. Preudhomme C., Vachee A., Lepelley P., Vanrumbeke M., Zandecki M., Quesnel B.et al. Inactivation of the retinoblastoma gene appears to be very uncommon in myelodysplastic syndromes. Br. J. Haematol. 87:1994;61-67.
180. Cinti C., Claudio P.P., Howard C.M., Neri L.M., Fu Y., Leoncini L.et al. Genetic alterations disrupting the nuclear localization of the retinoblastoma-related gene RB2/p130 in human tumor cell lines and primary tumors. Cancer Res. 60:2000;383-389.
181. Cinti C., Leoncini L., Nyongo A., Ferrari F., Lazzi S., Bellan C.et al. Genetic alterations of the retinoblastoma-related gene RB2/p130 identify different pathogenetic mechanisms in and among Burkitt's lymphoma subtypes. Am. J. Pathol. 156:2000;751-760.
182. Takimoto H., Tsukuda K., Ichimura K., Hanafusa H., Nakamura A., Oda M.et al. Genetic alterations in the retinoblastoma protein-related p107 gene in human hematologic malignancies. Biochem. Biophys. Res. Commun. 251:1998;264-268.
183. Hirama T., Koeffler H.P. Role of the cyclin-dependent kinase inhibitors in the development of cancer. Blood. 86:1995;841-854.
184. Deininger M.W., Vieira S.A., Parada Y., Banerji L., Peters G., Mahon F.X.et al. Direct relation between BCR-ABL tyrosine kinase activity and cyclin D2 expression in lymphoblasts. Cancer Res. 61:2001;8005-8013.
185. Jena N., Deng M., Sicinska E., Sicinski P., Daley G.Q. Critical role for cyclin D2 in BCR/ABL-induced proliferation of hematopoietic cells. Cancer Res. 62:2002;535-541.
186. Caligaris-Cappio F. Cellular interactions, immunodeficiency and autoimmunity in CLL. Hematol. Cell Ther. 42:2000;21-25.
187. Dighiero G., Binet J.L. When and how to treat chronic lymphocytic leukemia. N. Engl. J. Med. 343:2000;1799-1801.
188. Wolowiec D., Ciszak L., Kosmaczewska A., Bocko D., Teodorowska R., Frydecka I.et al. Cell cycle regulatory proteins and apoptosis in B-cell chronic lymphocytic leukemia. Haematologica. 86:2001;1296-1304.
189. Lam E.W.-F., Glassford J., Banerji L., Thomas N.S., Sicinski P., Klaus G.G. Cyclin D3 compensates for loss of cyclin D2 in mouse B-lymphocytes activated via the antigen receptor and CD40. J. Biol. Chem. 275:2000;3479-3484.
190. Lam E.W.-F., Glassford J., van der Sman J., Banerji L., Pizzey A.R., Thomas N.S.B.et al. Modulation of E2F activity in primary mouse B cells following stimulation via surface IgM and CD40 receptors. Eur. J. Immunol. 29:1999;3380-3389.
191. 0 to S phase transition in human primary B-lymphocytes. J. Biol. Chem. 274:1999;12009-12016.
192. Solvason N., Wu W.W., Parry D., Mahony D., Lam E.W., Glassford J.et al. Cyclin D2 is essential for BCR-mediated proliferation and CD5 B cell development. Int. Immunol. 12:2000;631-638.
193. Donnellan R., Chetty R. Cyclin E in human cancers. FASEB J. 13:1999;773-780.
194. Iida H., Towatari M., Tanimoto M., Morishita Y., Kodera Y., Saito H. Overexpression of cyclin E in acute myelogenous leukemia. Blood. 90:1997;3707-3713.
195. Erlanson M., Landberg G. Prognostic implications of p27 and cyclin E protein contents in malignant lymphomas. Leuk. Lymphoma. 40:2001;461-470.
196. 1-to-S transition. Mol. Cell Biol. 15:1995;3463-3469.
197. Spruck C.H., Won K.A., Reed S.I. Deregulated cyclin E induces chromosome instability. Nature. 401:1999;297-300.
198. Takeuchi S., Bartram C.R., Seriu T., Miller C.W., Tobler A., Janssen J.W.et al. Analysis of a family of cyclin-dependent kinase inhibitors: p15/MTS2/INK4B, p16/MTS1/INK4A, and p18 genes in acute lymphoblastic leukemia of childhood. Blood. 86:1995;755-760.
199. Stranks G., Height S.E., Mitchell P., Jadayel D., Yuille M.A., De Lord C.et al. Deletions and rearrangement of CDKN2 in lymphoid malignancy. Blood. 85:1995;893-901.
200. Siebert R., Willers C.P., Opalka B. Role of the cyclin-dependent kinase 4 and 6 inhibitor gene family p15, p16, p18 and p19 in leukemia and lymphoma. Leuk. Lymphoma. 23:1996;505-520.
201. Quelle D.E., Cheng M., Ashmun R.A., Sherr C.J. Cancer-associated mutations at the INK4a locus cancel cell cycle arrest by p16INK4a but not by the alternative reading frame protein p19ARF. Proc. Natl. Acad. Sci. U.S.A. 94:1997;669-673.
202. Quelle D.E., Zindy F., Ashmun R.A., Sherr C.J. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell. 83:1995;993-1000.
203. Taniguchi T., Endo H., Chikatsu N., Uchimaru K., Asano S., Fujita T.et al. Expression of p21(Cip1/Waf1/Sdi1) and p27(Kip1) cyclin-dependent kinase inhibitors during human hematopoiesis. Blood. 93:1999;4167-4178.
204. Merlo A., Herman J.G., Mao L., Lee D.J., Gabrielson E., Burger P.C.et al. 5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat. Med. 1:1995;686-692.
205. Drexler H.G. Review of alterations of the cyclin-dependent kinase inhibitor INK4 family genes p15, p16, p18 and p19 in human leukemia-lymphoma cells. Leukemia. 12:1998;845-859.
206. Krug U., Ganser A., Koeffler H.P. Tumor suppressor genes in normal and malignant hematopoiesis. Oncogene. 21:2002;3475-3495.
207. Esteller M., Corn P.G., Baylin S.B., Herman J.G. A gene hypermethylation profile of human cancer. Cancer Res. 61:2001;3225-3229.
208. Batova A., Diccianni M.B., Yu J.C., Nobori T., Link M.P., Pullen J.et al. Frequent and selective methylation of p15 and deletion of both p15 and p16 in T-cell acute lymphoblastic leukemia. Cancer Res. 57:1997;832-836.
209. Roman-Gomez J., Castillejo J.A., Jimenez A., Gonzalez M.G., Moreno F., Rodriguez Mdel C.et al. 5′ CpG island hypermethylation is associated with transcriptional silencing of the p21(CIP1/WAF1/SDI1) gene and confers poor prognosis in acute lymphoblastic leukemia. Blood. 99:2002;2291-2296.
210. Shen L., Kondo Y., Issa J.P., Garcia-Manero G. Lack of p21(CIP1) DNA methylation in acute lymphocytic leukemia. Blood. 100:2002;3432-3433. author reply 3433-4.
211. Kawamata N., Morosetti R., Miller C.W., Park D., Spirin K.S., Nakamaki T.et al. Molecular analysis of the cyclin-dependent kinase inhibitor gene p27/Kip1 in human malignancies. Cancer Res. 55:1995;2266-2269.
212. Takeuchi C., Takeuchi S., Ikezoe T., Bartram C.R., Taguchi H., Koeffler H.P. Germline mutation of the p27/Kip1 gene in childhood acute lymphoblastic leukemia. Leukemia. 16:2002;956-958.
213. Yokozawa T., Towatari M., Iida H., Takeyama K., Tanimoto M., Kiyoi H.et al. Prognostic significance of the cell cycle inhibitor p27Kip1 in acute myeloid leukemia. Leukemia. 14:2000;28-33.
214. Vrhovac R., Delmer A., Tang R., Marie J.P., Zittoun R., Ajchenbaum-Cymbalista F. Prognostic significance of the cell cycle inhibitor p27Kip1 in chronic B-cell lymphocytic leukemia. Blood. 91:1998;4694-4700.
215. Tsihlias J., Kapusta L., Slingerland J. The prognostic significance of altered cyclin-dependent kinase inhibitors in human cancer. Annu. Rev. Med. 50:1999;401-423.
216. Kikuchi T., Toyota M., Itoh F., Suzuki H., Obata T., Yamamoto H.et al. Inactivation of p57KIP2 by regional promoter hypermethylation and histone deacetylation in human tumors. Oncogene. 21:2002;2741-2749.
217. Li Y., Nagai H., Ohno T., Yuge M., Hatano S., Ito E.et al. Aberrant DNA methylation of p57(KIP2) gene in the promoter region in lymphoid malignancies of B-cell phenotype. Blood. 100:2002;2572-2577.
218. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell. 100:2000;57-70.
219. 1. Proc. Natl. Acad. Sci. U.S.A. 97:2000;14317-14322.
220. Hoessel R., Leclerc S., Endicott J.A., Nobel M.E., Lawrie A., Tunnah P. et al. Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases. Nat. Cell Biol. 1:1999;60-67.
221. Senderowicz A.M. The cell cycle as a target for cancer therapy: basic and clinical findings with the small molecule inhibitors flavopiridol and UCN-01. Oncologist. 7(Suppl. 3):2002;12-19.
222. Fischle W., Wang Y., Allis C.D. Histone and chromatin cross-talk. Curr. Opin. Cell Biol. 15:2003;172-183.
223. Bernstein B.E., Humphrey E.L., Erlich R.L., Schneider R., Bouman P., Liu J.S.et al. Methylation of histone H3 Lys 4 in coding regions of active genes. Proc. Natl. Acad. Sci. U.S.A. 99:2002;8695-8700.
224. Wong I.H., Ng M.H., Huang D.P., Lee J.C. Aberrant p15 promoter methylation in adult and childhood acute leukemias of nearly all morphologic subtypes: potential prognostic implications. Blood. 95:2000;1942-1949.
225. Herman J.G., Jen J., Merlo A., Baylin S.B. Hypermethylation-associated inactivation indicates a tumor suppressor role for p15INK4B. Cancer Res. 56:1996;722-727.
226. Herman J.G., Civin C.I., Issa J.P., Collector M.I., Sharkis S.J., Baylin S.B. Distinct patterns of inactivation of p15INK4B and p16INK4A characterize the major types of hematological malignancies. Cancer Res. 57:1997;837-841.
227. Uchida T., Kinoshita T., Nagai H., Nakahara Y., Saito H., Hotta T.et al. Hypermethylation of the p15INK4B gene in myelodysplastic syndromes. Blood. 90:1997;1403-1409.
228. Quesnel B., Fenaux P. P15INK4b gene methylation and myelodysplastic syndromes. Leuk. Lymphoma. 35:1999;437-443.
229. Tien H.F., Tang J.H., Tsay W., Liu M.C., Lee F.Y., Wang C.H.et al. Methylation of the p15(INK4B) gene in myelodysplastic syndrome: it can be detected early at diagnosis or during disease progression and is highly associated with leukaemic transformation. Br. J. Haematol. 112:2001;148-154.
230. Palmero I., Pantoja C., Serrano M. p19ARF links the tumour suppressor p53 to Ras. Nature. 395:1998;125-126.
231. Sherr C.J. Tumor surveillance via the ARF-p53 pathway. Genes Dev. 12:1998;2984-2991.
232. Silverman L.R., Demakos E.P., Peterson B.L., Kornblith A.B., Holland J.C., Odchimar-Reissig R.et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J. Clin. Oncol. 20:2002;2429-2440.
233. Christman J.K. 5-Azacytidine and 5-aza-2′-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy. Oncogene. 21:2002;5483-5495.
234. Daskalakis M., Nguyen T.T., Nguyen C., Guldberg P., Kohler G., Wijermans P.et al. Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2′-deoxycytidine (decitabine) treatment. Blood. 100:2002;2957-2964.
235. Chen H., Wu S. Hypermethylation of the p15(INK4B) gene in acute leukemia and myelodysplastic syndromes. Chin. Med. J. (Engl.). 115:2002;987-990.
236. Tessema M., Langer F., Dingemann J., Ganser A., Kreipe H., Lehmann U. Aberrant methylation and impaired expression of the p15(INK4b) cell cycle regulatory gene in chronic myelomonocytic leukemia (CMML). Leukemia. 17:2003;910-918.
237. Chim C.S., Liang R., Tam C.Y., Kwong Y.L. Methylation of p15 and p16 genes in acute promyelocytic leukemia: potential diagnostic and prognostic significance. J. Clin. Oncol. 19:2001;2033-2040.
238. Teofili L., Martini M., Luongo M., Diverio D., Capelli G., Breccia M.et al. Hypermethylation of GpG islands in the promoter region of p15(INK4b) in acute promyelocytic leukemia represses p15(INK4b) expression and correlates with poor prognosis. Leukemia. 17:2003;919-924.
239. Kusy S., Cmsnbfg F., Brizard A., Larsen C., Roche J. p14ARF, p15INK4b, and p16INK4a methylation status in chronic myelogenous leukemia. Blood. 101:2003;374-375.
240. Tan B., Cao P., Qi Z. Study of calcitonin gene methylation in chronic myeloid leukemia by using Hpa II-PCR. Hunan Yi Ke Da Xue Xue Bao. 24:1999;371-373.
241. Melki J.R., Vincent P.C., Clark S.J. Concurrent DNA hypermethylation of multiple genes in acute myeloid leukemia. Cancer Res. 59:1999;3730-3740.
242. Wu S., Xie G., Bai R., Wang Y., Zhu P. Semi-quantitative study of calcitonin gene methylation in myelodysplastic syndrome. Chin. Med. J. (Engl.). 111:1998;690-693.
243. Roman J., Castillejo J.A., Jimenez A., Bornstein R., Gonzalez M.G., del Carmen Rodriguez M.et al. Hypermethylation of the calcitonin gene in acute lymphoblastic leukaemia is associated with unfavourable clinical outcome. Br. J. Haematol. 113:2001;329-338.
244. Chen C.Y., Tsay W., Tang J.L., Shen H.L., Lin S.W., Huang S.Y.et al. SOCS1 methylation in patients with newly diagnosed acute myeloid leukemia. Genes Chromosomes Cancer. 37:2003;300-305.
245. Yang M.Y., Liu T.C., Chang J.G., Lin P.M., Lin S.F. JunB gene expression is inactivated by methylation in chronic myeloid leukemia. Blood. 101:2003;3205-3211.
246. Roman-Gomez J., Castillejo J.A., Jimenez A., Cervantes F., Boque C., Hermosin L.et al. Cadherin-13, a mediator of calcium-dependent cell-cell adhesion, is silenced by methylation in chronic myeloid leukemia and correlates with pretreatment risk profile and cytogenetic response to interferon alfa. J. Clin. Oncol. 21:2003;1472-1479.
247. Cameron E.E., Bachman K.E., Myohanen S., Herman J.G., Baylin S.B. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat. Genet. 21:1999;103-107.
248. Coral S., Sigalotti L., Altomonte M., Engelsberg A., Colizzi F., Cattarossi I.et al. 5-Aza-2′-deoxycytidine-induced expression of functional cancer testis antigens in human renal cell carcinoma: immunotherapeutic implications. Clin. Cancer Res. 8:2002;2690-2695.
249. Sigalotti L., Coral S., Altomonte M., Natali L., Gaudino G., Cacciotti P.et al. Cancer testis antigens expression in mesothelioma: role of DNA methylation and bioimmunotherapeutic implications. Br. J. Cancer. 86:2002;979-982.
250. Sigalotti L., Coral S., Nardi G., Spessotto A., Cortini E., Cattarossi I.et al. Promoter methylation controls the expression of MAGE2, 3 and 4 genes in human cutaneous melanoma. J. Immunother. 25:2002;16-26.
251. Adams S.P., Sahota S.S., Mijovic A., Czepulkowski B., Padua R.A., Mufti G.J.et al. Frequent expression of HAGE in presentation chronic myeloid leukaemias. Leukemia. 16:2002;2238-2242.
252. Sigalotti L., Altomonte M., Colizzi F., Degan M., Rupolo M., Zagonel V. et al. 5-Aza-2′-deoxycytidine (decitabine) treatment of hematopoietic malignancies: a multimechanism therapeutic approach? Blood. 101:2003;4644-4646. discussion 4645-6.
253. Cheng J.C., Matsen C.B., Gonzales F.A., Ye W., Greer S., Marquez V.E.et al. Inhibition of DNA methylation and reactivation of silenced genes by zebularine. J. Natl. Cancer Inst. 95:2003;399-409.
254. El-Osta A. On the use of DNA methylation inhibitors and the reversal of transcriptional silencing. Blood. 101:2003;1656. author reply 1657-8.
255. Nakayama M., Wada M., Harada T., Nagayama J., Kusaba H., Ohshima K.et al. Hypomethylation status of CpG sites at the promoter region and overexpression of the human MDR1 gene in acute myeloid leukemias. Blood. 92:1998;4296-4307.
256. Leith C.P., Kopecky K.J., Chen I.M., Eijdems L., Slovak M.L., McConnell T.S.et al. Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group Study. Blood. 94:1999;1086-1099.
257. Yoshida Y. Hypothesis: apoptosis may be the mechanism responsible for the premature intramedullary cell death in the myelodysplastic syndrome. Leukemia. 7:1993;144-146.
258. Raza A., Gezer S., Mundle S., Gao X.Z., Alvi S., Borok R.et al. Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes. Blood. 86:1995;268-276.
259. Greenberg P.L. Apoptosis and its role in the myelodysplastic syndromes: implications for disease natural history and treatment. Leuk. Res. 22:1998;1123-1136.
260. Parcharidou A., Raza A., Economopoulos T., Papageorgiou E., Anagnostou D., Papadaki T.et al. Extensive apoptosis of bone marrow cells as evaluated by the in situ end-labelling (ISEL) technique may be the basis for ineffective haematopoiesis in patients with myelodysplastic syndromes. Eur. J. Haematol. 62:1999;19-26.
261. Parker J.E., Mufti G.J. Excessive apoptosis in low risk myelodysplastic syndromes (MDS). Leuk. Lymphoma. 40:2000;1-24.
262. Parker J.E., Mufti G.J., Rasool F., Mijovic A., Devereux S., Pagliuca A. The role of apoptosis, proliferation, and the Bcl-2-related proteins in the myelodysplastic syndromes and acute myeloid leukemia secondary to MDS. Blood. 96:2000;3932-3938.
263. Cleary M.L. The bcl-2 gene and protein in malignant lymphomas. Bull. Cancer. 78:1991;187-193.
264. Jiang M., Milner J. Bcl-2 constitutively suppresses p53-dependent apoptosis in colorectal cancer cells. Genes Dev. 17:2003;832-837.
265. Chao D.T., Korsmeyer S.J. BCL-2 family: regulators of cell death. Annu. Rev. Immunol. 16:1998;395-419.
266. Campos L., Rouault J.P., Sabido O., Oriol P., Roubi N., Vasselon C.et al. High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. Blood. 81:1993;3091-3096.
267. Lagasse E., Weissman I.L. bcl-2 inhibits apoptosis of neutrophils but not their engulfment by macrophages. J. Exp. Med. 179:1994;1047-1052.
268. Traver D., Akashi K., Weissman I.L., Lagasse E. Mice defective in two apoptosis pathways in the myeloid lineage develop acute myeloblastic leukemia. Immunity. 9:1998;47-57.
269. Kogan S.C., Brown D.E., Shultz D.B., Truong B.T., Lallemand-Breitenbach V., Guillemin M.C.et al. BCL-2 cooperates with promyelocytic leukemia retinoic acid receptor alpha chimeric protein (PMLRARalpha) to block neutrophil differentiation and initiate acute leukemia. J. Exp. Med. 193:2001;531-543.
270. Campos L., Sabido O., Rouault J.P., Guyotat D. Effects of BCL-2 antisense oligodeoxynucleotides on in vitro proliferation and survival of normal marrow progenitors and leukemic cells. Blood. 84:1994;595-600.
271. Reed J.C. Apoptosis-targeted therapies for cancer. Cancer Cell. 3:2003;17-22.
272. List A., Beran M., DiPersio J., Slack J., Vey N., Rosenfeld C.S.et al. Opportunities for Trisenox (arsenic trioxide) in the treatment of myelodysplastic syndromes. Leukemia. 17:2003;1499-1507.
273. List A.F. New approaches to the treatment of myelodysplasia. Oncologist. 7(Suppl. 1):2002;39-49.
274. Vogelstein B., Lane D., Levine A.J. Surfing the p53 network. Nature. 408:2000;307-310.
275. Gustafsson B., Christenson B., Hjalmar V., Winiarski J. Cellular expression of MDM2 and p53 in childhood leukemias with poor prognosis. Med. Pediatr. Oncol. 34:2000;117-124.
276. Kanavaros P., Stefanaki K., Rontogianni D., Darivianaki K., Vlychou M., Papadaki E.et al. Immunohistochemical detection of p53, mdm2, waf1/p21, and Ki67 proteins in bone marrow biopsies in myelodysplastic syndroms, acute myelogenous leukaemias and chronic myeloproliferative disorders. Clin. Exp. Pathol. 47:1999;231-238.
277. Fang B., Roth J.A. Tumor-suppressing gene therapy. Cancer Biol. Ther. 2:2003;S115-S121.
278. Ali A., Mundle S.D., Ragasa D., Reza S., Shetty V., Mativi B.Y.et al. Sequential activation of caspase-1 and caspase-3-like proteases during apoptosis in myelodysplastic syndromes. J. Hematother. Stem Cell Res. 8:1999;343-356.
279. Mundle S.D., Gregory S.A., Preisler H.D., Raza A. Enzymatic programming of apoptotic cell death. Pathobiology. 64:1996;161-170.
280. Bouscary D., Chen Y.L., Guesnu M., Picard F., Viguier F., Lacombe C.et al. Activity of the caspase-3/CPP32 enzyme is increased in "early stage" myelodysplastic syndromes with excessive apoptosis, but caspase inhibition does not enhance colony formation in vitro. Exp. Hematol. 28:2000;784-791.
281. Santini V. Amifostine: chemotherapeutic and radiotherapeutic protective effects. Expert Opin. Pharmacother. 2:2001;479-489.
282. List A.F., Brasfield F., Heaton R., Glinsmann-Gibson B., Crook L., Taetle R.et al. Stimulation of hematopoiesis by amifostine in patients with myelodysplastic syndrome. Blood. 90:1997;3364-3369.
283. Invernizzi R., Pecci A., Travaglino E., Gobbi P.G., Malabarba L., Ramajoli I.et al. Clinical and biological effects of treatment with amifostine in myelodysplastic syndromes. Br. J. Haematol. 118:2002;246-250.
284. Raza A., Qawi H., Lisak L., Andric T., Dar S., Andrews C.et al. Patients with myelodysplastic syndromes benefit from palliative therapy with amifostine, pentoxifylline, and ciprofloxacin with or without dexamethasone. Blood. 95:2000;1580-1587.
285. Garcia-Manero G., Faderl S., Giles F., Thomas D., Cortes J., O'Brien S. et al. A phase I study of idarubicin dose escalation with amisfostine and high-dose cytarabine in patients with relapsed acute myelogenous leukemia and myelodysplastic syndromes. Haematologica. 87:2002;804-807.
286. Musch E., Malek M., Chrissafidou A., Amifostine plus erythropoietin in a patient with low-risk myelodysplastic syndrome Ann. Hematol. 82:2003;244-246.
287. Hellstrom-Lindberg E., Gulbrandsen N., Lindberg G., Ahlgren T., Dahl I.M., Dybedal I.et al. A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life. Br. J. Haematol. 120:2003;1037-1046.
288. Hellstrom-Lindberg E., Birgegard G., Carlsson M., Carneskog J., Dahl I.M., Dybedal I.et al. A combination of granulocyte colony-stimulating factor and erythropoietin may synergistically improve the anaemia in patients with myelodysplastic syndromes. Leuk. Lymphoma. 11:1993;221-228.
289. Bowen D., Culligan D., Jowitt S., Kelsey S., Mufti G., Oscier D.et al. Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes. Br. J. Haematol. 120:2003;187-200.
290. Neumeister P., Jaeger G., Eibl M., Sormann S., Zinke W., Linkesch W. Amifostine in combination with erythropoietin and G-CSF promotes multilineage hematopoiesis in patients with myelodysplastic syndrome. Leuk. Lymphoma. 40:2001;345-349.
291. Zorat F., Shetty V., Dutt D., Lisak L., Nascimben F., Allampallam K.et al. The clinical and biological effects of thalidomide in patients with myelodysplastic syndromes. Br. J. Haematol. 115:2001;881-894.
292. Strupp C., Germing U., Aivado M., Misgeld E., Haas R., Gattermann N. Thalidomide for the treatment of patients with myelodysplastic syndromes. Leukemia. 16:2002;1-6.
293. Cortes J., Kantarjian H., Albitar M., Thomas D., Faderl S., Koller C.et al. A randomized trial of liposomal daunorubicin and cytarabine versus liposomal daunorubicin and topotecan with or without thalidomide as initial therapy for patients with poor prognosis acute myelogenous leukemia or myelodysplastic syndrome. Cancer. 97:2003;1234-1241.
294. Allampallam K., Shetty V.T., Raza A. Cytokines and MDS. Cancer Treat. Res. 108:2001;93-100.
295. Hofmann W.K., Kalina U., Koschmieder S., Seipelt G., Hoelzer D., Ottmann O.G. Defective megakaryocytic development in myelodysplastic syndromes. Leuk. Lymphoma. 38:2000;13-19.
296. Ogata K., Tamura H. Thrombopoietin and myelodysplastic syndromes. Int. J. Hematol. 72:2000;173-177.
297. Luo S.S., Ogata K., Yokose N., Kato T., Dan K. Effect of thrombopoietin on proliferation of blasts from patients with myelodysplastic syndromes. Stem Cells. 18:2000;112-119.
298. Hashimoto S., Toba K., Fuse I., Watanabe K., Takahashi H., Abe T.et al. Thrombopoietin activates the growth of megakaryoblasts in patients with chronic myeloproliferative disorders and myelodysplastic syndrome. Eur. J. Haematol. 64:2000;225-230.
299. Kalina U., Hofmann W.K., Koschmieder S., Wagner S., Kauschat D., Hoelzer D.et al. Alteration of c-mpl-mediated signal transduction in CD34(+) cells from patients with myelodysplastic syndromes. Exp. Hematol. 28:2000;1158-1163.
300. Glinsmann-Gibson B., Spier C., Baier M., Taetle R., Broudy V.C., List A.F. Mast cell growth factor (c-kit ligand) restores growth of multipotent progenitors in myelodysplastic syndrome. Leukemia. 8:1994;827-832.
301. Brada S., de Wolf J., Hendriks D., Esselink M., Ruiters M., Vellenga E. The supportive effects of erythropoietin and mast cell growth factor on CD34+/CD36- sorted bone marrow cells of myelodysplasia patients. Blood. 88:1996;505-510.
302. Buchler T., Michalek J., Kovarova L., Musilova R., Hajek R. Dendritic cell-based immunotherapy for the treatment of hematological malignancies. Hematology. 8:2003;97-104.
303. Cui Y., Kelleher E., Straley E., Fuchs E., Gorski K., Levitsky H.et al. Immunotherapy of established tumors using bone marrow transplantation with antigen gene-modified hematopoietic stem cells. Nat. Med. 9:2003;952-958.
304. Pinilla-Ibarz J., Cathcart K., Korontsvit T., Soignet S., Bocchia M., Caggiano J.et al. Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses. Blood. 95:2000;1781-1787.
305. Schwartz J., Pinilla-Ibarz J., Yuan R.R., Scheinberg D.A. Novel targeted and immunotherapeutic strategies in chronic myeloid leukemia. Semin. Hematol. 40:2003;87-96.
306. Cathcart K, Pinilla-Ibarz J, Korontsvit T, Schwartz J, Zakhaleva V, Papadopoulus EB, et al. A multivalent bcr-abl fusion peptide vaccination trial in patients with chronic myeloid leukemia. Blood 2003 (in press).
307. Molldrem J.J., Lee P.P., Kant S., Wieder E., Jiang W., Lu S.et al. Chronic myelogenous leukemia shapes host immunity by selective deletion of high-avidity leukemia-specific T cells. J. Clin. Invest. 111:2003;639-647.
308. Molldrem J.J., Lee P.P., Wang C., Felio K., Kantarjian H.M., Champlin R.E.et al. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat. Med. 6:2000;1018-1023.
309. Hoos A., Levey D.L. Vaccination with heat shock protein-peptide complexes: from basic science to clinical applications. Expert Rev. Vaccines. 2:2003;369-379.
310. Rosenfeld C., Cheever M.A., Gaiger A. WT1 in acute leukemia, chronic myelogenous leukemia and myelodysplastic syndrome: therapeutic potential of WT1 targeted therapies. Leukemia. 17:2003;1301-1312.
311. Oka Y., Tsuboi A., Elisseeva O.A., Udaka K., Sugiyama H. WT1 as a novel target antigen for cancer immunotherapy. Curr. Cancer Drug Targets. 2:2002;45-54.
312. Stevenson F.K., Anderson K.C. Immunotherapy for multiple myeloma: insights from other models. Leuk. Res. 26:2002;403-405.
313. Stevenson F.K., Rosenberg W. DNA vaccination: a potential weapon against infection and cancer. Vox. Sang. 80:2001;12-18.
314. Rice J., Buchan S., Stevenson F.K. Critical components of a DNA fusion vaccine able to induce protective cytotoxic T cells against a single epitope of a tumor antigen. J. Immunol. 169:2002;3908-3913.
315. Sasaki S., Takeshita F., Xin K.Q., Ishii N., Okuda K. Adjuvant formulations and delivery systems for DNA vaccines. Methods. 31:2003;243-254.
316. Krieg A.M. CpG motifs: the active ingredient in bacterial extracts? Nat. Med. 9:2003;831-835.
317. Fujisawa S., Togawa J., Tanaka M., Koharazawa H., Aoba M., Fujita H.et al. De novo acute myelogenous leukemia with trilineage myelodysplasia associated with t(8;21)(q22;q22). Int. Med. 38:1999;607-611.
318. Gamou T., Kitamura E., Hosoda F., Shimizu K., Shinohara K., Hayashi Y.et al. The partner gene of AML1 in t(16;21) myeloid malignancies is a novel member of the MTG8(ETO) family. Blood. 91:1998;4028-4037.
319. Dissing M., Le Beau M.M., Pedersen-Bjergaard J. Inversion of chromosome 16 and uncommon rearrangements of the CBFB and MYH11 genes in therapy-related acute myeloid leukemia: rare events related to DNA-topoisomerase II inhibitors? J. Clin. Oncol. 16:1998;1890-1896.
320. Shimada H., Arai Y., Sekiguchi S., Ishii T., Tanitsu S., Sasaki M. Generation of the NUP98-HOXD13 fusion transcript by a rare translocation, t(2;11)(q31;p15), in a case of infant leukaemia. Br. J. Haematol. 110:2000;210-213.
321. Hatano Y., Miura I., Nakamura T., Yamazaki Y., Takahashi N., Miura A.B. Molecular heterogeneity of the NUP98/HOXA9 fusion transcript in myelodysplastic syndromes associated with t(7;11)(p15;p15). Br. J. Haematol. 107:1999;600-604.
322. Nishiyama M., Arai Y., Tsunematsu Y., Kobayashi H., Asami K., Yabe M.et al. 11p15 translocations involving the NUP98 gene in childhood therapy-related acute myeloid leukemia/myelodysplastic syndrome. Genes Chromosomes Cancer. 26:1999;215-220.
323. Peeters P., Wlodarska I., Baens M., Criel A., Selleslag D., Hagemeijer A.et al. Fusion of ETV6 to MDS1/EVI1 as a result of t(3;12)(q26;p13) in myeloproliferative disorders. Cancer Res. 57:1997;564-569.
324. Golub T.R. TEL gene rearrangements in myeloid malignancy. Hematol. Oncol. Clin. North Am. 11:1997;1207-1220.
325. Yagasaki F., Jinnai I., Yoshida S., Yokoyama Y., Matsuda A., Kusumoto S.et al. Fusion of TEL/ETV6 to a novel ACS2 in myelodysplastic syndrome and acute myelogenous leukemia with t(5;12)(q31;p13). Genes Chromosomes Cancer. 26:1999;192-202.
326. Buijs A., van Rompaey L., Molijn A.C., Davis J.N., Vertegaal A.C., Potter M.D.et al. The MN1-TEL fusion protein, encoded by the translocation (12;22)(p13;q11) in myeloid leukemia, is a transcription factor with transforming activity. Mol. Cell Biol. 20:2000;9281-9293.
327. Kondo T., Minamino N., Nagamura-Inoue T., Matsumoto M., Taniguchi T., Tanaka N. Identification and characterization of nucleophosmin/B23/numatrin which binds the anti-oncogenic transcription factor IRF-1 and manifests oncogenic activity. Oncogene. 15:1997;1275-1281.
328. Blutters-Sawatzki R., Borkhardt A., Grathwohl J., Repp R., Rheinisch-Becker I., Bohle R.M.et al. Secondary acute myeloid leukemia with translocation (4;11) and MLL/AF4 rearrangement in a 15-year-old boy treated for common acute lymphoblastic leukemia 11 years earlier. Ann. Hematol. 70:1995;31-35.
329. Borkhardt A., Bojesen S., Haas O.A., Fuchs U., Bartelheimer D., Loncarevic I.F.et al. The human GRAF gene is fused to MLL in a unique t(5;11)(q31;q23) and both alleles are disrupted in three cases of myelodysplastic syndrome/acute myeloid leukemia with a deletion 5q. Proc. Natl. Acad. Sci. U.S.A. 97:2000;9168-9173.
330. Atlas M., Head D., Behm F., Schmidt E., Zeleznik-Le N.H., Roe B.A.et al. Cloning and sequence analysis of four t(9;11) therapy-related leukemia breakpoints. Leukemia. 12:1998;1895-1902.
331. Dreyling M.H., Schrader K., Fonatsch C., Schlegelberger B., Haase D., Schoch C.et al. MLL and CALM are fused to AF10 in morphologically distinct subsets of acute leukemia with translocation t(10;11): both rearrangements are associated with a poor prognosis. Blood. 91:1998;4662-4667.
332. Rowley J.D., Reshmi S., Sobulo O., Musvee T., Anastasi J., Raimondi S.et al. All patients with the T(11;16)(q23;p13.3) that involves MLL and CBP have treatment-related hematologic disorders. Blood. 90:1997;535-541.
333. Ahuja H.G., Felix C.A., Aplan P.D. The t(11;20)(p15;q11) chromosomal translocation associated with therapy-related myelodysplastic syndrome results in an NUP98-TOP1 fusion. Blood. 94:1999;3258-3261.
334. Nakao K., Nishino M., Takeuchi K., Iwata M., Kawano A., Arai Y.et al. Fusion of the nucleoporin gene, NUP98, and the putative RNA helicase gene, DDX10, by inversion 11 (p15q22) chromosome translocation in a patient with etoposide-related myelodysplastic syndrome. Int. Med. 39:2000;412-415.
335. Soekarman D., von Lindern M., Daenen S., de Jong B., Fonatsch C., Heinze B.et al. The translocation (6;9) (p23;q34) shows consistent rearrangement of two genes and defines a myeloproliferative disorder with specific clinical features. Blood. 79:1992;2990-2997.
336. Borrow J., Stanton V.P. Jr., Andresen J.M., Becher R., Behm F.G., Chaganti R.S.et al. The translocation t(8;16)(p11;p13) of acute myeloid leukaemia fuses a putative acetyltransferase to the CREB-binding protein. Nat. Genet. 14:1996;33-41.
337. Padua R.A., le Pogam C., Larghero J., Robin M., Muszlak S., Fric J.et al. Fusion-oncogene DNA based vaccine induces protective immunity: example of a targeted therapy in an acute promyelocytic leukemia animal model. Nat. Med. 9:2003;1413-1417.